Advanced Enzyme Technologies Limited — Investor Meet, 17-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Advanced Enzyme Technologies reported strong Q2 FY26 financials: revenue grew 26% YoY to INR 184.5 Cr, EBITDA surged 42% YoY to INR 60.1 Cr (33% margin), and PAT rose 34% YoY to INR 44.7 Cr. H1 FY26 saw 32% revenue growth to INR 370.4 Cr. Growth was broad-based across Human Healthcare, Bioprocessing (especially food), and Specialized Manufacturing. Management noted US market slowdown due to tariffs, impacting EBITDA by an estimated INR 10-11 Cr in the worst case. The company maintains its mid-double-digit growth outlook despite global uncertainties, focusing on R&D, new products, and potential M&A in animal feed/probiotics. Margins of 30-32% EBITDA are expected as the new normal.